Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lakshminarayanan Nandagopal (NPI 1770897548)

Field	Value
Entity Type	Individual
Organization	Lakshminarayanan Nandagopal
Address	4501 Empire Ct
City	Fredericksburg
State	VA
ZIP	22408
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 3, 2010

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider's Medicare business is concentrated in oncology immunotherapy: the single-payer Medicare book totals $2.9M and the top three Medicare codes — J9271 ($731K, 26.5%), J9299 ($474.7K, 17.2%), and J9144 ($376.2K, 13.6%) — together account for 57.4% of the provider's total Medicare revenue, which indicates infusion of high-cost biologic agents is the primary revenue driver. The code mix (checkpoint inhibitors and monoclonal antibodies) is consistent with a hematology/oncology infusion practice that relies heavily on outpatient administration of systemic cancer therapies.

Operationally this profile looks like an infusion-centered oncology practice with on-site supportive services: in addition to high volumes of J9271, J9299, and J9144, the provider reports activity in chemotherapy administration codes such as 96413 (562 claims, $55.6K revenue) and infusion add-on codes like 96367 (938 claims, $20.6K revenue), plus lab/diagnostic items (85025, 80053, 36415). Together these entries suggest the clinician administers and monitors parenteral oncology treatments and performs routine lab work in the outpatient setting rather than operating purely as a consult-only service.

The provider is effectively single-payer at the claims level: Medicare revenue is $2.9M while there is no Medicaid billing on file, so payer mix risk and growth opportunities will be almost entirely tied to Medicare volumes and reimbursement dynamics rather than Medicaid contracts. Analysts should treat this NPI as Medicare-dependent when modeling revenue sensitivity to rate changes or utilization shifts.

Competitive standing on the high-revenue immunotherapy agents is generally solid but not dominant: J9271 ranks #553 of 1841 (69th percentile, described as typical/unremarkable) and J9299 ranks #169 of 505 (67th percentile, typical/unremarkable), while J9144 ranks #213 of 615 (64th percentile, typical/unremarkable). These percentiles indicate healthy, routine-volume participation nationally for those core oncology agents rather than leadership positions in the specialty.

There are several codes where this provider reports volumes that are high relative to national peers: J0897 (denosumab) ranks #581 of 10057 (94th percentile, notably above typical national volume) and J1439 (ferric carboxymaltose) ranks #49 of 1209 (96th percentile, notably above typical national volume). Such notably-above-typical activity in supportive/intravenous iron and bone-modifying therapy suggests the practice also treats treatment-related complications or supportive care needs at above-average rates.

Routine office E/M and chemotherapy administration activity are elevated versus peers: 99214 is reported at 773 claims ($71.9K, 2.6% of Medicare revenue) and ranks #21146 of 479517 (96th percentile, notably above typical national volume), while 96413 ranks #503 of 7514 (93th percentile, notably above typical national volume). These signals point to sustained outpatient follow-up and active therapy throughput — useful metrics for capacity planning and competitor benchmarking.

Several lower-revenue but operationally informative items show unusually high claim counts relative to revenue: J1439 lists 109.5K claims at $1 avg paid/claim for $109.5K revenue, and 36415 shows 2.2K claims ($17.2K revenue) with a 99th-percentile rank labeled typical/unremarkable. The presence of large claim counts for small-dollar items indicates a high-volume throughput of routine procedures (blood draws, IV iron administrations) supporting the infusion business model.

Provider tenure is long enough to evaluate stable behavior: the NPI was enumerated 2010-08-03 (~16 years ago), so current patterns likely reflect an established practice rather than a newly started operation and should be interpreted with that history in mind.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

97 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,000	$40	$731K
J9299	Injection, nivolumab, 1 mg	19,780	$20	$474.7K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,900	$40	$376.2K
J0897	Injection, denosumab, 1 mg	14,400	$20	$259.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,620	$40	$238.3K
J1439	Injection, ferric carboxymaltose, 1 mg	109,500	$1	$109.5K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,900	$30	$72.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	770	$90	$71.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	560	$100	$55.6K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	5,500	$10	$55K

Showing 1–10 of 97

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 97 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Lakshminarayanan Nandagopal — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

97 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	26	110	12,800	$40	$610.9K
J9299	5	30	12,920	$20	$335.4K
J9144	15	60	8,280	$40	$332.7K
J1569	2	30	3,000	$40	$135.7K
J0897	16	340	2,820	$20	$89.3K
J9264	6	10	6,800	$10	$86.1K
J1449	1	10	2,640	$30	$66.9K
Q5119	19	40	1,570	$20	$39.6K
Q5114	2	10	1,160	$30	$37.4K
88185	20	60	620	$20	$34.3K

Showing 1–10 of 97

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lakshminarayanan Nandagopal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Lakshminarayanan Nandagopal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Compass Counseling Services Of Northern Virginia	VA	Community/Behavioral Health Agency	$0	$54.4M
Spotsylvania Medical Center Inc	VA	General Acute Care Hospital	$0	$31M
Pinnacle Treatment Centers Va-i, LLC	VA	Methadone Clinic	$152.9K	$15.6M
Assured Corporation	VA	Home Health Agency	$0	$12.8M
Charles Maurer	VA	Hematology & Oncology Physician	$2.8M	$0
Bonny Moore	VA	Hematology & Oncology Physician	$2.7M	$0
Matthew Whitehurst	VA	Medical Oncology Physician	$2.1M	$0
Sudeep Menachery	VA	Hematology & Oncology Physician	$1.9M	$0
Arijit Chanda	VA	Interventional Cardiology Physician	$571.6K	$0
Anh Vu	VA	Cardiovascular Disease Physician	$549.9K	$90

Lakshminarayanan Nandagopal — Billing Profile & Reimbursement Data

Sign up for Lakshminarayanan Nandagopal — Billing Profile & Reimbursement Data policy alerts

Lakshminarayanan Nandagopal — Billing Profile & Reimbursement Data

Sign up for Lakshminarayanan Nandagopal — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References